“Retained monitoring” enables you to stay several steps ahead of your competitors and helps you to predict their moves in the market place or regulatory authorities approval of a competing drug.
This service will give you an early warning indicator as well as threat and risk assessments on market and competitor moves, including launch dates of generic or biosimilar entries.
These CI projects last six months or longer. These are comprehensive programmes including a combination of public domain, paid databases, primary (KOLs, PIs, personnel at competitor companies), and conference intelligence gathering, analysis and synthesis on an ongoing basis. The majority of clients choose to run a strategic simulation at the end of 12 months of CI monitoring.